Dermapharm Holding SE/€DMP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Dermapharm Holding SE
Dermapharm Holding SE is a pharmaceutical company based in Germany, specializing in the development, production, and commercialization of off-patent branded pharmaceuticals. The company focuses on several key product segments, including dermatological and allergy products, vitamins, and food supplements. Established in 1991, Dermapharm has developed a diversified product portfolio with over 900 marketing authorizations. It operates production facilities in Europe and maintains a strong sales presence in Germany and other European countries. The company's strategic positioning is bolstered by its vertically integrated business model, which enables efficient product development and manufacturing processes.
- Ticker
- €DMP
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 3,619
- Headquarters
- Grünwald, Germany
- Website
- ir.dermapharm.de
DMP Metrics
BasicAdvanced
€1.9B
13.78
€2.77
0.85
€0.88
2.30%
Price and volume
Market cap
€1.9B
Beta
0.85
52-week high
€51.60
52-week low
€32.85
Average daily volume
17K
Dividend rate
€0.88
Financial strength
Current ratio
1.712
Quick ratio
0.75
Long term debt to equity
1.932
Total debt to equity
2.193
Dividend payout ratio (TTM)
33.07%
Interest coverage (TTM)
5.48%
Profitability
EBITDA (TTM)
309.649
Gross margin (TTM)
65.41%
Net profit margin (TTM)
12.39%
Operating margin (TTM)
21.06%
Effective tax rate (TTM)
24.50%
Revenue per employee (TTM)
€330,000
Management effectiveness
Return on assets (TTM)
7.11%
Return on equity (TTM)
25.57%
Valuation
Price to earnings (TTM)
13.784
Price to revenue (TTM)
1.708
Price to book
3.5
Price to tangible book (TTM)
-3.46
Price to free cash flow (TTM)
9.353
Free cash flow yield (TTM)
10.69%
Free cash flow per share (TTM)
4.084
Dividend yield (TTM)
2.30%
Forward dividend yield
2.30%
Growth
Revenue change (TTM)
0.40%
Earnings per share change (TTM)
39.03%
3-year revenue growth (CAGR)
1.34%
3-year earnings per share growth (CAGR)
6.63%
3-year dividend per share growth (CAGR)
-5.72%
Bulls say / Bears say
Branded pharmaceuticals remain a growth engine: H1 segment revenue rose 11.6%, with management reporting 4–5% organic growth and strong progress in brands such as Wobenzym and its allergy portfolio. (Deutsche Börse, StockAnalysis)
Profitability is growing faster than sales: H1 adjusted EBITDA rose 10.3% to €163.2 million and the margin widened by 1.8 percentage points to 27.6%. Earnings also improved in other healthcare products and parallel imports. (Deutsche Börse)
Cash generation strengthened: H1 operating cash flow increased by €35 million, while cash conversion improved by 17 percentage points to 65% of EBITDA. That gives the group more capacity to fund investment and meet debt commitments. (StockAnalysis)
Accounting and valuation uncertainty remains. BaFin is examining the accounting for a €63.2 million receivable and related-party disclosures; after a fall in Dutch cannabis prices, Dermapharm recorded a €30 million impairment and says further valuation changes remain possible. (Reuters, StockAnalysis)
The €181 million share buyback was partly debt-funded, taking leverage to about 3 times adjusted EBITDA and reducing the equity ratio to roughly 24%. Although the company said it remains within its bank covenants, the higher debt load limits financial flexibility. (StockAnalysis)
Top-line growth is uneven: group revenue increased only 2.9% in H1, while sales fell 14.0% in parallel imports and 1.2% in other healthcare products. Acquisitions helped offset those declines, leaving growth more dependent on continued branded-pharmaceutical momentum. (Deutsche Börse)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
DMP Financial Performance
Revenues and expenses
DMP Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing DMP
AllEURUSDGBP
Fund name | Fund size | €DMP weighting |
|---|---|---|
Vanguard Germany All Cap£VGER | €258M | 0.02% |
Vanguard ESG Developed Europe All Cap£V3EA | €125M | 0.00% |
Vanguard ESG Developed Europe All Cap£V3EL | €35M | 0.00% |
Vanguard FTSE Global All-cap$VALU | $199M | 0.00% |
Vanguard FTSE Global All-cap€VGLA | €171M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.